The surface marker classification of non-Hodgkin's lymphomas has demonstrated its value in refining existing morphologic systems of classification and thus in guiding clinical decisions in otherwise ambiguous cases. This accomplishment, in itself significant, may provide the key to the development of effective monospecific therapeutic agents that could be directed at target cells.